Moderna, Inc. (MRNA)
Moderna GAAP EPS of -$0.51 beats by $1.67, revenue of $1.02B beats by $150.11M
(Earnings Call Insights) Moderna lowers 2025 cash cost guidance by $900M while advancing late-stage pipeline
Moderna_Focus On Cancer Vaccines, Not Buyout (StrongBuy)
Moderna - More Downside In The Stock But The Cancer Vaccine Offers Potential (Sell)
Moderna: RSV Upside Slim, Cash Burn Heavy (Sell)
